Societe Generale Asks Staff to Return to Office Four Days a Week
Save
Societe Generale SA asked its employees who are on hybrid work schedules to return to the office four days a week, according to an internal memo seen by Bloomberg News.
'I would like to inform you of the executive committee's decision to harmonize rapidly our working from home policy within the group, on the basis of a maximum of one day per week,' Societe Generale Chief Executive Officer Slawomir Krupa wrote in the memo sent Thursday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
The European Space Agency and Dassault Aviation paving the way for potential collaborations
PRESS RELEASE June 20, 2025 The European Space Agency and Dassault Aviation paving the way for potential collaborationsThe European Space Agency (ESA) has signed a Letter of Intent (LoI) with Dassault Aviation, a French civilian and military aircraft manufacturer recognized worldwide for its excellence, underlying their common interest to develop a closer relationship. ESA, with its ambitious strategy for space exploration, Explore2040, is seeking innovative solutions for capabilities development to reach and return from Low Earth Orbit (LEO), Moon and Mars, and supports the advancement of selected critical enabling technologies to be used and demonstrated in particular in LEO, such as hypervelocity re-entry. Dassault Aviation, also a leader in aerospace engineering, is developing its space activities with a focus on the design of a reusable spaceplane based on lifting bodies shapes that bridge aeronautical and space technologies. Their interest in automated LEO platforms suitable for commercial and institutional markets, led them to develop a vehicle concept called 'Véhicule Orbital Réutilisable de Transport et d'Exploration (VORTEX)', designed for research in space, transport of cargo to and from space stations, and a range of in-orbit services. This project is based on a considerable expertise in spaceplanes having participated in numerous programmes like Hermes, NASA X-38 Crew Rescue vehicle, ESA Intermediate eXperimental Vehicle (IXV) demonstrator, and Airborne Reusable Hypersonic Experimental Vehicle (VEHRA) concepts. 'Dassault Aviation's decades of expertise in aeronautical and space systems, perfectly position them to pioneer critical space technologies', said Josef Aschbacher, Director General of the European Space Agency. 'With VORTEX, Dassault is contributing to strengthening European capacities and securing sovereign access to space in a strongly growing and competitive space sector. We look forward to combining our expertise and working hand-in-hand for a stronger Europe in space.' 'Our Vortex roadmap aims to strengthen Europe's essential sovereign capabilities and meet the new challenges of the space economy. This letter of intent is a perfect recognition of the complementary expertise of the European Space Agency and Dassault Aviation in the development of critical technologies and innovative space solutions,' declared Eric Trappier, Chaiman and CEO of Dassault Aviation. As such, the signatories of the LoI, have identified a mutual interest in developing a closer relationship with the potential to commonly derisking critical technologies as well as to further explore the potential for collaboration in areas such as LEO destinations and particularly around orbital vehicules. As such, both foresee an interest to cooperate on a scaled down suborbital version of VORTEX, serving as a testbed, with a focus on, but not limited to: Designing, testing and qualifying key technologies and components. New materials and integration processes. Assessing the feasibility to include future payloads in case of the integration of a dedicated bay on the end-product. This joint work will be based on exchanging relevant information and conducting studies or preparatory activities, to help establish respective roles and responsibilities in the realisation of potential joint activities, leveraging on each side's capabilities. 'Europe benefits from a wide range of diverse and complementary skills. Enlarging the European industrial base is key for new opportunities arising in Space Exploration, aiming at more autonomy,' said Daniel Neuenschwander, Director of Human and Robotic Exploration at ESA. About the European Space Agency The European Space Agency (ESA) provides Europe's gateway to is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe's space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. ESA has 23 Member States: Austria, Belgium, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. Latvia, Lithuania and Slovakia are Associate Members. ESA has established formal cooperation with other four Member States of the EU. Canada takes part in some ESA programmes under a Cooperation Agreement. By coordinating the financial and intellectual resources of its members, ESA can undertake programmes and activities far beyond the scope of any single European country. It is working in particular with the EU on advancing the Galileo and Copernicus programmes as well as with Eumetsat for the development of meteorological missions. Learn more about ESA at Media contact: media@ About Dassault Aviation With over 10,000 military and civil aircraft delivered in more than 90 countries over the last century, Dassault Aviation has built up expertise recognized worldwide in the design, production, sale and support of all types of aircraft, ranging from the Rafale fighter, to the high-end Falcon family of business jets, military drones and space systems. In 2024, sales amounted to € 6.2 billion. Dassault Aviation has 14,600 employees. Dassault Aviation – PRESS CONTACTS Corporate Communications Stéphane Fort: +33 (0)1 47 11 86 90 - Mathieu Durand: +33 (0)1 47 11 85 88 - Export CommunicationsNathalie Bakhos Tel: +33 (0)1 47 11 84 12 Attachment PR_ESA Dassault VF 1Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
an hour ago
- Washington Post
Kevin Durant buys minority stake in Paris Saint-Germain, will advise club on basketball expansion
PARIS — NBA star Kevin Durant has purchased a minority stake in Champions League winner Paris Saint-Germain , the French soccer club said Friday. Qatar Sports Investments, PSG's majority shareholder, signed an investment and strategic partnership agreement with Durant, the club said in a statement. Financial terms were not disclosed.
Yahoo
an hour ago
- Yahoo
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market RulesNantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a 'Questions and Answers' document for all its shareholders and informs the market of ongoing procedures, in line with its commitment to holding the annual General Meeting with transparency, serene debates, and compliance with market rules. In line with its continuous information and transparency approach towards shareholders, the Company has published a "Questions and Answers" document, accessible at the following address: intended to answer the main questions of shareholders regarding recent events. Nicolas Poirier, CEO of OSE, states: "We have a responsibility to all those who expect seriousness and results from OSE, primarily the patients. We cannot leave the false information communicated to the market unanswered. For example, there is no plan to use venture debt instruments. In response to these unfounded rumors, we have decided to publish this "Questions and Answers" document. An exchange with all shareholders will be organized soon in the same spirit." Following the declaration of a concerted action and the submission of several resolutions aimed at significantly altering the composition of the Board of Directors by a group of shareholders1, the Company reminds the market, that it had requested and obtained, by order of the President of the Nantes Commercial Court dated June 10, 2025, the postponement of the General Meeting initially scheduled for June 25, 20252. The "group of shareholders" notified the Company today of their challenge to this decision, through a request for the retraction of the June 10, 2025 order, with a hearing scheduled for Tuesday, June 24, 2025. The postponement of the General Meeting to a later date, aims to address the concerns expressed by certain shareholders in this tense context and to ensure that the consultation of its shareholders can take place in a serene democratic framework, ensuring complete and fair information. This general meeting cannot be a stage for attempts to destabilize and spread erroneous information about the Company. In this regard, OSE Immunotherapeutics has filed a request today with the Nantes Commercial Court, within the framework of an accelerated procedure (known as "fixed date"), for an action against this same group of shareholders. This action concerns the regularity of the declaration of the concerted action, with the aim of ensuring compliance with the principles of transparency governing shareholder democracy ahead of the Company's next General Meeting. Subject to the evolution of legal proceedings, the Company currently plans to hold the General Meeting on September 30, 2025. In this context, the Board of Directors reaffirms its commitment in favor of a transparent, responsible and constructive dialogue among all stakeholders. This commitment is reflected in the procedures and actions undertaken by the Company but also by the joint mobilization of the management and the Board of Directors to install a dialogue with the "group of shareholders". A constructive and formal framework for exchange has thus been proposed to move forward together in the interest of the Company and all its shareholders. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. 1 Press release of June 9, 20252 Press release of June 11, 2025 Attachment EN_250620_FINALSign in to access your portfolio
